KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
KISIMA-02
Phase 1 other active
Quick answer
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer for G12D/G12V Pancreatic Ductal Adenocarcinoma is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- G12D/G12V Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active